MSU
TEVA icon

Maple Securities USA’s Teva Pharmaceuticals TEVA Stock Holding History

Maple Securities USA’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-13,768
Closed -$740K – 253
2014
Q3 		$740K Buy
+13,768
New +$729K 0.08% 92
2014
Q2 		– Sell
-9,520
Closed -$503K – 292
2014
Q1 		$503K Buy
+9,520
New +$440K 0.04% 86

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Maple Securities USA's TEVA Position: Q4 2014 in Review

Maple Securities USA sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 13,768 shares — an estimated $740K sold.

Maple Securities USA first reported a position in TEVA in Q1 2014 and held it in 2 quarters. The position peaked at $740K in Q3 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

  • Maple Securities USA reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Maple Securities USA sold 13,768 Teva Pharmaceuticals shares in Q4 2014, an estimated $740K.
  • Maple Securities USA first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Maple Securities USA's Teva Pharmaceuticals position peaked at $740K in Q3 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Maple Securities USA's 13F filing for Q4 2014, filed 11 Feb 2015.